1. Short title

This Act may be cited as the "Veterans with ALS Reporting Act".

2. Report on Amyotrophic Lateral Sclerosis in Veterans

(a) In general - Not later than one year after the date of the enactment of this Act, the Secretary of Veterans Affairs, in consultation with the Director of the Centers for Disease Control and Prevention, shall submit to Congress a report on the incidence and prevalence of amyotrophic lateral sclerosis (commonly known as "ALS"). Such report shall include—

(1) an assessment of the incidence and prevalence of amyotrophic lateral sclerosis in veterans (as defined in section 101 of title 38, United States Code);

(2) a description of the resources and support that the the Centers for Disease Control and the Department of Veterans Affairs provides to veterans with amyotrophic lateral sclerosis;

(3) a description of any deficiencies in the resources and support described in paragraph (2);

(4) a strategy to develop and test risk reduction strategies intended to lower the incidence and prevalence of amyotrophic lateral sclerosis among veterans;

(5) a strategy to develop a pathway for veterans receiving amyotrophic lateral sclerosis care within Department of Veterans Affairs clinics to participate in clinical trials and research sponsored by the Department of Veterans Affairs; and

(6) any recommendations for the enactment of legislation to address the challenges or needs associated with lowering the incidence and prevalence of amyotrophic lateral sclerosis among veterans.

(b) Tracking of amyotrophic lateral sclerosis in members and veterans - The Secretary of Veterans Affairs shall track the prevalence of amyotrophic lateral sclerosis in veterans using the amyotrophic lateral sclerosis registry and biorepository of the Centers for Disease Control and Prevention.

(c) Subsequent reports - Not later than three years after the date of the enactment of this Act, and every three years thereafter, the Secretary of Veterans Affairs shall submit to Congress an update to the report required under subsection (a) and information on the prevalence of amyotrophic lateral sclerosis tracked under subsection (b).